Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych MEQs / SAQsConsultation-liaison psychiatry

Psych MEQs / SAQs · Consultation-liaison psychiatry

TBI psychiatry — depression, aggression, capacity (MEQ)

FRANZCP-style MEQ on post-TBI depression, aggression ladder including beta-blockers, personality change framing, and decision-specific capacity.

20 marks20 min
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
A 46-year-old man is 5 months after moderate TBI (nadir GCS 11, PTA 6 days, bifrontal contusions). He has anhedonia, early waking, and passive suicidal ideation. On the rehab unit he has punched a wall twice when frustrated; staff want 'regular olanzapine'. His wife says he is disinhibited and 'not himself' but he scores 28/30 on a brief cognitive screen and wants to sign a complex business sale this week. (i) Formulate the psychiatric syndromes. (ii) Outline non-drug and drug management of depression and aggression with named evidence. (iii) Address capacity for the business sale. (iv) List disposition and risk priorities. (20 marks)

Model answer

Reveal model answer

(i) Formulation. Concurrent syndromes: (1) major depression due to another medical condition (TBI) — anhedonia, insomnia, passive SI months after moderate injury; depression is common and outcome-relevant after TBI.[1] (2) Aggression/behavioural dyscontrol linked to bifrontal injury and frustration intolerance — clinical correlates include frontal pathology and mood comorbidity.[5] (3) Features of personality change due to another medical condition (disinhibition, not himself) that may coexist with depression and must not be collapsed into "just depression" or primary personality disorder.[6] Not established primary schizophrenia; not day-3 PTA only (now 5 months).

(ii) Management. Depression: adapted psychotherapy + SSRI. Sertraline is the most trial-visible agent (Fann treatment RCT; Jorge prevention RCT) — start 25–50 mg oral daily, titrate, monitor suicide risk, hyponatraemia, interactions; avoid bupropion if seizure concern.[2][3] Aggression: medical/environmental review first; behavioural structure with rehab team. Prefer beta-blockers (e.g. propranolol low-and-slow with BP/HR monitoring) per expert recommendations rather than standing high-dose olanzapine for non-psychotic dyscontrol; reserve low-dose short-term atypical antipsychotic only for imminent danger; avoid chronic benzo/anticholinergic strategies.[4][5][6]

(iii) Capacity. Decision-specific analysis of the business sale: understanding, retaining, weighing, communicating. Brief cognitive screen 28/30 does not prove executive weighing for a complex financial act; frontal disinhibition and depression both threaten valid consent. Pause major transactions, involve appropriate legal substitute pathways under local law, reassess after treatment and with neuropsychology if needed.[6]

(iv) Disposition and risk. Active suicide risk plan; violence/impulse risk on unit and at home; substance screen; family education; stepwise rehab and community CL/neuropsychiatry follow-up; driving/work fitness deferred until team clearance; document least-restrictive legal status if needed.[1][6]

Common errors

Collapsing everything into primary personality disorder; standing high-dose olanzapine without beta-blocker consideration; equating MMSE-like scores with complex financial capacity; ignoring suicide risk in post-TBI depression.[1][4][6]

Examiner notes

Reward dual diagnosis of depression + personality change, named sertraline trials, beta-blocker priority, and sophisticated capacity reasoning.[2][3][4]

References

  1. [1]Bombardier CH, Fann JR, Temkin NR, et al. Rates of major depressive disorder and clinical outcomes following traumatic brain injury JAMA, 2010.PMID 20483970
  2. [2]Fann JR, Bombardier CH, Temkin N, et al. Sertraline for Major Depression During the Year Following Traumatic Brain Injury: A Randomized Controlled Trial J Head Trauma Rehabil, 2017.PMID 28520672
  3. [3]Jorge RE, Acion L, Burin DI, et al. Sertraline for Preventing Mood Disorders Following Traumatic Brain Injury: A Randomized Clinical Trial JAMA Psychiatry, 2016.PMID 27626622
  4. [4]Plantier D, Luauté J, SOFMER group Drugs for behavior disorders after traumatic brain injury: Systematic review and expert consensus leading to French recommendations for good practice Ann Phys Rehabil Med, 2016.PMID 26797170
  5. [5]Tateno A, Jorge RE, Robinson RG Clinical correlates of aggressive behavior after traumatic brain injury J Neuropsychiatry Clin Neurosci, 2003.PMID 12724455
  6. [6]Rao V, Koliatsos V, Ahmed F, et al. Neuropsychiatric disturbances associated with traumatic brain injury: a practical approach to evaluation and management Semin Neurol, 2015.PMID 25714869